Evofem Biosciences to Present at Stifel Virtual Healthcare Conference

Rhea-AI Summary

Evofem Biosciences (NASDAQ: EVFM) will present at the Stifel Virtual Healthcare Conference on November 18, 2020 at 4:00 p.m. ET. The presentation can be accessed live and archived via the Evofem website. Evofem focuses on developing innovative products for women's sexual and reproductive health, including the hormone-free contraceptive Phexxi™, and is currently evaluating EVO100 in a Phase 3 trial for preventing urogenital infections.

SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced it will present at the Stifel Virtual Healthcare Conference on Wednesday November 18, 2020 at 4:00 p.m. ET.

To access the live and archived webcast of this fireside chat, visit the Investors section of the Evofem Biosciences website at www.evofem.com, and select the Events and Presentations tab. 

About Evofem Biosciences
Evofem Biosciences, Inc., (NASDAQ: EVFM) is a commercial-stage biopharmaceutical company committed to developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from certain sexually transmitted infections (STIs). The Company's first commercial product, Phexxi™ (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy. The Company is evaluating EVO100 in a Phase 3 clinical trial, 'EVOGUARD,' for the prevention of urogenital Chlamydia trachomatis and Neisseria gonorrhoeae infection in women. For more information, please visit www.evofem.com.

Phexxi™ is a trademark of Evofem Biosciences, Inc.

Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775

Media Contact
Ellen Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-stifel-virtual-healthcare-conference-301171760.html

SOURCE Evofem Biosciences, Inc.

FAQ

When will Evofem Biosciences present at the Stifel Virtual Healthcare Conference?

Evofem Biosciences will present on November 18, 2020 at 4:00 p.m. ET.

How can I access the Evofem presentation at the Stifel Conference?

The presentation can be accessed live and archived on the Evofem Biosciences website in the Investors section.

What is Phexxi™ and its relevance to Evofem Biosciences?

Phexxi™ is the first hormone-free, prescription vaginal gel approved in the U.S. for pregnancy prevention, developed by Evofem.

What is the focus of Evofem Biosciences' Phase 3 trial involving EVO100?

The Phase 3 trial, called EVOGUARD, evaluates EVO100 for the prevention of urogenital infections caused by Chlamydia trachomatis and Neisseria gonorrhoeae.